Exchange: NASDAQ·Updated 04:27 AM EDT

RXRX News

News
all
press releases
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
Zacks
More News
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered byread more...
Benzinga
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Zacks
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
Zacks
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Zacks
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Zacks
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Zacks
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Zacks
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.